Volume 40, Issue 1, Pages (January 2004)

Slides:



Advertisements
Similar presentations
Harro Frauendorf. Introduction Infection: microbes vs. host Viruses try to secure a niche for replication Host must limit pathogen's advance Type 1 interferons.
Advertisements

INTERFERONS. Interferons Interferons are proteins, immunologist prefer to call them cytokines –They are glycosylated The name originates from the fact.
 Binding sites for several key transcription factors, including nuclear factor (NF)-kB and various interferon regulatory factor (IRF) proteins, are present.
INNATE IMMUNITY II.
Interferons Cytokine family important for innate immunity against viruses Three classes of IFNs according to the receptor used Type I IFNs essential for.
Interferons Type I IFN IFN-ω IFN-  IFN-  IFN-  IFN-  IFN-  IFN-  Type II IFN IFN-  Type III IFN IFN-   IL  B  IFN-   IL  IFN-   IL.
Interferons Induction of synthesis Induction of antiviral activity Antiviral activities induced by interferons  and  Antiviral activities induced by.
EASL Clinical Practice Guidelines: Vascular diseases of the liver Journal of Hepatology Volume 64, Issue 1, Pages (January 2016) DOI: /j.jhep
Epidermal growth factor receptor tyrosine kinase inhibitors as initial therapy for non- small cell lung cancer: Focus on epidermal growth factor receptor.
Volume 46, Issue 3, Pages (March 2007)
Host – hepatitis C viral interactions: The role of genetics
Interferons: Type I José Ignacio Saldana, Imperial College London, UK
An integration of deep viral suppression with sequential immune modulation (cocktail therapy) to restore antiviral capacity: The future of chronic hepatitis.
Type I Interferon Signal Pathway. InterferonInterferon (IFNs) is a group of signaling proteins made and released by host cells in response to the presence.
Hepatic CD141+IFNλ+ DC subset: One against all?
Nat. Rev. Rheumatol. doi: /nrrheum
Novel insights in the interplay between inflammation and metabolic diseases: A role for the pathogen sensing kinase PKR  Nicolas Marsollier, Pascal Ferré,
Matthew T. Kitson, Stuart K. Roberts  Journal of Hepatology 
Volume 52, Issue 3, Pages (March 2010)
NS5A inhibitors in the treatment of hepatitis C
RNA interference in biology and disease
Interferon-λ: Immune Functions at Barrier Surfaces and Beyond
Toll-like receptors: Applications to dermatologic disease
Jean-Charles Nault, Jessica Zucman-Rossi  Journal of Hepatology 
Mechanisms of action of interferon and nucleoside analogues
Immigration and viral hepatitis
Figure 1 Regulation of key antiviral responses in pancreatic β cells
Sterol-izing Innate Immunity
Ype P. de Jong, Charles M. Rice, Alexander Ploss  Journal of Hepatology 
JAK inhibitors in dermatology: The promise of a new drug class
David G. Bowen, Christopher M. Walker  Journal of Hepatology 
Natural history and predictors of severity of chronic hepatitis C virus (HCV) and human immunodeficiency virus (HIV) co-infection  Anaïs Vallet-Pichard,
Hepatitis C core protein – The “core” of immune deception?
Signalling pathways in alcohol-induced liver inflammation
Simon Haas, Andreas Trumpp  Developmental Cell 
Hepatocyte-like cells differentiated from human induced pluripotent stem cells (iHLCs) are permissive to hepatitis C virus (HCV) infection: HCV study.
Marc van der Valk, Hans L. Zaaijer, Arnon P. Kater, Janke Schinkel 
A dive into the complexity of type I interferon antiviral functions
Inhibition of mammalian target of rapamycin: Two goals with one shot?
Volume 61, Issue 1, Pages S69-S78 (November 2014)
Daniel J. Felmlee, Thomas F. Baumert  Journal of Hepatology 
Darius Moradpour, Arash Grakoui, Michael P. Manns 
Autophagy in the liver Journal of Hepatology
Interferon-α and -β in kidney inflammation
Timothy M. Block, Ju-Tao Guo  Gastroenterology 
Host-targeting agents for prevention and treatment of chronic hepatitis C – Perspectives and challenges  Mirjam B. Zeisel, Joachim Lupberger, Isabel Fofana,
Mona Malz, Federico Pinna, Peter Schirmacher, Kai Breuhahn 
Met as a therapeutic target in HCC: Facts and hopes
Bin Gao, Hua Wang, Fouad Lafdil, Dechun Feng  Journal of Hepatology 
Economics of chronic hepatitis B and hepatitis C
Nanna Fyhrquist, Sampsa Matikainen, Antti Lauerma 
Volume 132, Issue 1, Pages 5-6 (January 2007)
Matthew D. Daugherty, Harmit S. Malik  Cell Host & Microbe 
Immigration and viral hepatitis
Treatment failure in hepatitis C: Mechanisms of non-response
HCV targeting of patients with cirrhosis
Schematic summary of the mechanisms by which tick-borne Phlebovirus NSs proteins inhibit the canonical IFN induction and signaling pathways. Schematic.
Innate immunity and HCV
Volume 51, Issue 2, Pages (August 2009)
Mechanism-Based Precision Therapy for the Treatment of Primary Immunodeficiency and Primary Immunodysregulatory Diseases  Jennifer W. Leiding, MD, Lisa.
T-bet Runs INTERFERence
Innate Recognition of Viruses
Chimeric mouse model of hepatitis B virus infection
Primary immunodeficiencies: A rapidly evolving story
Primary immunodeficiencies may reveal potential infectious diseases associated with immune-targeting mAb treatments  László Maródi, MD, PhD, Jean-Laurent.
Philippe Metz, Antje Reuter, Silke Bender, Ralf Bartenschlager 
Host – hepatitis C viral interactions: The role of genetics
Volume 66, Issue 3, Pages (March 2017)
Johannes Vermehren, James S. Park, Ira M. Jacobson, Stefan Zeuzem 
Reversion of disease manifestations after HCV eradication
Presentation transcript:

Volume 40, Issue 1, Pages 184-186 (January 2004) Protease inhibitors for treatment of chronic hepatitis C—a new target for the magic bullet identified  Peter Ferenci  Journal of Hepatology  Volume 40, Issue 1, Pages 184-186 (January 2004) DOI: 10.1016/j.jhep.2003.10.015

Fig. 1 Simplified scheme of activation of type I interferons (IFNs) by viral infections. HCVs like most viruses have evolved strategies to block and interfere with the IFN pathway. (1) Blocking of IFN induction/expression by a serine protease in the NS3/NS4 region inhibits the activation of IRF-3 [13]. (2) Interaction of PKR with HCV E2 protein abolishes antiviral activity of IFN [3]. Abbreviations: IKK, IκB kinase; IRF, IFN-regulatory factor; ISG, IFN-stimulated genes; JAK, Janus kinase; Mx, myxovirus-resistance proteins; OAS, oligoadenylate synthetase; PKR, IFN-inducible protein kinase; STAT, signal transducer and activator of transcription; TYK, tyrosine kinase. Journal of Hepatology 2004 40, 184-186DOI: (10.1016/j.jhep.2003.10.015)